Kimberly-Clark Completes $49 Billion Kenvue Acquisition, Adding Tylenol and Neutrogena

Kimberly-Clark said today, Nov. 2, that it has completed its acquisition of Kenvue. The deal closed almost exactly a year after the companies announced it on Nov. 3, 2025. It values Kenvue at roughly $49 billion including debt.

Kenvue stock, which traded on the New York Stock Exchange as KVUE, has ceased trading. Kimberly-Clark (NASDAQ: KMB) closed Monday's session at $108.25, up 0.3%, according to CNBC's market data.

What Kenvue shareholders get

Each Kenvue share converts into $3.50 in cash plus 0.14625 shares of Kimberly-Clark stock. The companies valued that package at $21.01 per share when they announced the deal, based on Kimberly-Clark's Oct. 31, 2025 closing price.

The stock portion floats with Kimberly-Clark's price, so the value at closing differs from that announced figure.

The dividend picture also shifts. Kenvue's latest quarterly dividend was $0.21 per share. Kimberly-Clark's is $1.28 per share, and Kenvue holders' dividend income will now come from the Kimberly-Clark shares they receive. Kimberly-Clark holders were expected to own about 54% of the combined company, and former Kenvue holders about 46%.

The combined company

The merged business holds 10 billion-dollar brands: Huggies, Cottonelle, Depend, Kleenex, Kotex and Scott from Kimberly-Clark, plus Tylenol, Neutrogena, Listerine and Johnson's Baby from Kenvue. Kimberly-Clark says it serves consumers in more than 175 countries.

It will report through four segments:

• North America, about $18.0 billion in annual sales
• Europe, Middle East and Africa, about $5.0 billion
• Asia Pacific Focus Markets (Greater China, Australia/New Zealand, South Korea, Indonesia), about $4.3 billion
• Enterprise Markets (Latin America including Brazil, India, Southeast Asia, Japan), about $4.3 billion

Carlos De Jesus, who ran Kenvue's North America business, becomes President of North America. Craig Slavtcheff is Chief R&D Officer. Mike Hsu stays chairman and CEO.

The board now has 13 directors, three of them from Kenvue's board. Mae C. Jemison, Christa S. Quarles and Jaime A. Ramirez stepped down from Kimberly-Clark's board effective immediately.

Regulatory competition concerns forced some trimming before closing. Kimberly-Clark agreed to exit European feminine care by selling that business to Turkish manufacturer Dilek. Kenvue sold its feminine care brands in Australia, New Zealand and Brazil.

The savings target

Kimberly-Clark reiterated $2.1 billion in anticipated run-rate synergies. That includes $1.9 billion in cost reductions within three years. CNBC's account of the company's targets adds $500 million in incremental profit from higher revenue, partly offset by $300 million in reinvestment.

Hsu also stressed dividend safety, according to BigGo Finance's account of the company's stated goals. He is targeting earnings-per-share accretion by the second year and leverage of about 2.0 times.

The cost target is the part with a number attached. Cost cuts of this size in a combined company with a large global footprint mean headcount and overhead decisions that Kimberly-Clark has not yet detailed.

Growth case and the doubts

Hsu's pitch is that Kimberly-Clark can run Kenvue's brands better than Kenvue did. On CNBC, he said his company has spent a decade building what he called "world-class CPG capability" in retailer relationships, digital, advertising and innovation. He added: "I still would say we're in the early innings of developing that capability, but I think we're further along than Kenvue."

CNBC's Jim Cramer has pointed to weakness in Kenvue's operations, particularly e-commerce. He sees that as the opening for Kimberly-Clark. Cramer's Investing Club added the stock to its portfolio in early September and has since added to the position three times, including twice in October below $98 a share. Hsu's claim of a stronger operating model is his own, and it will be tested by results.

Kenvue was spun out of Johnson & Johnson's consumer health division in May 2023. In its latest quarter it posted organic sales growth of 2.9%.

Two watch items follow the deal, per BigGo Finance and CNBC's accounts: rising raw material costs and the legal fight surrounding Tylenol. CNBC reports that in July a federal appeals court resurrected more than 500 lawsuits alleging prenatal Tylenol use contributed to autism or ADHD in children, and that about two weeks ago a U.S. appeals court said it wouldn't reconsider that ruling.

Index changes

S&P Dow Jones Indices announced Oct. 30 that Okta will replace Kenvue in the S&P 500 before the open on Wednesday, Nov. 4. Kimberly-Clark stays in the index.

The integration timeline is the next test: Kimberly-Clark has three years to show the $1.9 billion in cost cuts, and the Tylenol litigation remains unresolved.